Study on the Relationship Between PTPRO Methylation in Plasma and Efficacy Neoadjuvant Chemotherapy in Patients with Early Breast Cancer

Figures & data

Table 1 Univariate Analysis of Clinical Data and NAC Efficacy in Patients with Breast Cancer

Clinical Features	Total	Non-pCR	pCR	χ^2/t	P-value
Number of patients, n (%)	82 (100)	49 (59.8)	33 (40.2)		–
Age, years	47.9±7.8	47.6±7.8	48.3±7.8	−0.41	0.68
cT, n (%)				4.096	0.25
1	7 (8.5)	6 (7.2)	1 (1.3)
2	59 (72.0)	32 (39.0)	27 (33)
3	6 (7.3)	5 (6.1)	1 (1.2)
4	10 (12.2)	6 (7.3)	4 (4.9)
cN, n (%)				0.562	0.91
0	19 (23.2)	11 (13.4)	8 (9.8)
1	53 (64.6)	33 (40.2)	20 (24.4)
2	8 (9.8)	4 (4.9)	4 (4.9)
3	2 (2.4)	1 (1.2)	1 (1.2)
Pathological type, n (%)				2.097	0.15
Invasive ductal carcinoma	79 (96.3)	46 (56.1)	33 (40.2)
Others	3 (3.7)	3 (3.7)	0 (0)
Histological grade, n (%)				0.913	0.34
Grade II	64 (78.0)	40 (48.8)	24 (29.2)
Grade III	18 (22.0)	9 (11.0)	9 (11.0)
ER, n (%)				2.299	0.13
Negative	34 (41.4)	17 (20.7)	17 (20.7)
Positive	48 (58.6)	32 (39.0)	16 (19.6)
PR, n (%)				2.256	0.13
Negative	27 (33.0)	13 (15.9)	14 (17.1)
Positive	55 (67.0)	36 (43.9)	19 (23.1)
HER2, n (%)				7.645	0.01
Negative	45 (54.9)	33 (40.2)	12 (14.7)
Positive	37 (45.1)	16 (15.9)	21 (29.2)
Ki67, n (%)				1.16	0.28
≤30%	28 (34.1)	19 (23.2)	9 (10.9)
>30%	54 (65.9)	30 (36.6)	24 (29.3)
PTPRO methylation status before NAC, n (%)				11.186	0.001
Negative	34 (41.5)	13 (15.9)	21 (25.6)
Positive	48 (58.5)	36 (43.9)	12 (14.6)

Note: Bold P-value indicates significance.

Abbreviations: cT, clinical tumor stage; cN, clinical nodal stage; ER, estrogen receptor; PR, progesterone receptor; HER2, epidermal growth factor receptor 2; PTPRO, protein tyrosine phosphatase receptor-type O; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response.

Table 2 Logistic Regression Analysis of NAC Efficacy in Breast Cancer Patients

Clinical Features	OR value	95% CI	P-value
HER2 (positive vs negative)	2.95	1.11–7.87	0.03
PTPRO methylation status before NAC (positive vs negative)	0.24	0.09–0.65	0.005

Note: Bold P-value indicates significance.

Abbreviations: HER2, epidermal growth factor receptor 2; PTPRO, protein tyrosine phosphatase receptor-type O; NAC, neoadjuvant chemotherapy.

Table 3 Univariate Analysis of NAC Efficacy in Early Breast Cancer Patients with Positive Pre-NAC PTPRO Methylation

Clinical Features	Total	Non-PCR	pCR	χ^2/t	P-value
Number of patients, n (%)	48 (100)	36 (0.75)	12 (0.25)		–
Age, years	48.8±7.6	48.4±7.9	50.2±6.7	−0.712	0.48
cT, n (%)				2.971	0.40
1	6 (12.5)	6 (12.5)	0 (0)
2	35 (72.9)	25 (52.1)	10 (20.8)
3	5 (10.4)	4 (8.3)	1 (2.1)
4	2 (4.2)	1 (2.1)	1 (2.1)
cN, n (%)				0.342	0.84
0	13 (27.1)	9 (18.8)	4 (8.3)
1	30 (62.5)	23 (47.9)	7 (14.6)
2	5 (10.4)	4 (8.3)	1 (2.1)
Pathological type, n (%)				0.696	0.40
Invasive ductal carcinoma	46 (95.8)	34 (70.8)	12 (25.0)
Others	2 (4.2)	2 (4.2)	0 (0)
Histological grade, n (%)				0.593	0.44
Grade II	36 (75.0)	28 (58.3)	8 (16.7)
Grade III	12 (25.0)	8 (16.7)	4 (8.3)
ER, n (%)				0.254	0.61
Negative	21 (43.8)	15 (31.3)	6 (12.5)
Positive	27 (56.2)	21 (43.7)	6 (12.5)
PR, n (%)				1.488	0.22
Negative	17 (35.4)	11 (22.9)	6 (12.5)
Positive	31 (64.6)	25 (52.1)	6 (12.5)
HER2, n (%)				1.488	0.22
Negative	31 (64.6)	25 (52.1)	6 (12.5)
Positive	17 (35.4)	11 (22.9)	6 (12.5)
Ki67, n (%)				0.134	0.71
≤30%	14 (29.2)	11 (22.9)	3 (6.3)
>30%	34 (70.8)	25 (52.1)	9 (18.7)
PTPRO methylation status after NAC, n (%)				9.341	0.004
Negative	15 (31.3)	7 (14.6)	8 (16.7)
Positive	33 (68.7)	29 (60.4)	4 (8.3)

Note: Bold P-value indicates significance.

Abbreviations: cT, clinical tumor stage; cN, clinical nodal stage; ER, estrogen receptor; PR, progesterone receptor; HER2, epidermal growth factor receptor 2; PTPRO, protein tyrosine phosphatase receptor-type O; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response.